Company / Free Cash Flow
Amylyx Pharmaceuticals, Inc. Free Cash Flow History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$123.5M
FY2025
5-year range
-$182.4M / $10.7M
FY2021-FY2025
Trend
+26.4%
vs FY2024
Sector context
#119 of 194
Health Care
What the data says
At -$123M, Amylyx Pharmaceuticals, Inc.'s free cash flow ranks #119 of 194 in the Health Care sector. Free Cash Flow has fluctuated over the past 5 years, ranging from -$182M in FY2022 to $11M in FY2023.
Based on SEC 10-K filings.
-$123M in FY2025.
Declined from $11M to -$123M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#119 of 194 in Health CareTop 61% of 194This company -$123.5M Sector average $470.6M
▼
-126.2% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 26.4% year-over-year.
- Ranks #119 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2023.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$123.5M | +26.4% |
| FY2024 | -$167.8M | -1671.5% |
| FY2023 | $10.7M | +105.9% |
| FY2022 | -$182.4M | -142.7% |
| FY2021 | -$75.2M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026